Cancer Immunology, Immunotherapy

, Volume 29, Issue 2, pp 87–92 | Cite as

Synergistic induction of lymphokine (IL-2)-activated killer activity by IL-2 and the polysaccharide lentinan, and therapy of spontaneous pulmonary metastases

  • Ken-ichiro Yamasaki
  • Saburo Sone
  • Takashi Yamashita
  • Takeshi Ogura
Original Articles


Spleen cells of C57BL/6N mice bearing lung metastases were induced to the cytotoxic state by subcutaneous injection of recombinant human interleukin-2 (IL-2) at a minimum dose of 5×104 U/mouse three times a day for 3 consecutive days. A single intraperitoneal injection of lentinan alone at concentrations of up to 10 mg/kg body weight did not render spleen cells cytotoxic to P-29 cells, but a combination of subthreshold doses of these agents (5×104 U/ml IL-2 and 5 mg/kg lentinan) induced significant in vivo lymphokine-activated killer activity in spleen cells of tumor-bearing mice. Similarly, spleen cells from mice treated i.p. with lentinan became cytotoxic on in vitro treatment with IL-2. The in vitro responsiveness of spleen cells to IL-2 was maximal 3 days after i.p. injection of lentinan. Synergism between IL-2 and lentinan was also observed in mice bearing spontaneous lung micrometastases: neither IL-2 (<5×104 U/mouse) nor lentinan (<2.5 mg/kg) alone had a therapeutic effect, but multiple injections of IL-2 with a single injection of lentinan resulted in significant inhibition of spontaneous pulmonary metastases. From these results we conclude that IL-2 and lentinan in combination are more effective than either one alone for inducing destruction of pulmonary metastases.


Polysaccharide Intraperitoneal Injection Lung Metastasis Subcutaneous Injection Spleen Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Brunda MJ, Bellantoni D, Sulich V (1987) In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer 40:365Google Scholar
  2. 2.
    Chihara G, Hamuro J, Maeda YY, Arai Y, Fukuoka F (1970) Fractionation and purification of the polysaccharides with marked antitumor activity, especially lentinan, from Lentinus edodes (Berk.) Sing. (an edible mushroom). Cancer Res 30:2776Google Scholar
  3. 3.
    Damle NK, Doyle LV, Bradley EC (1986) Interleukin-2-activated human killer cells are derived from phenotypically heterogeneous precursors. J Immunol 137:2814Google Scholar
  4. 4.
    Dennert G, Tuckor D (1973) Antitumor polysaccharide lentinan — a T cell adjuvant. J Natl Cancer Inst 51:1727Google Scholar
  5. 5.
    Donohue JH, Rosenberg SA (1983) The fate of interleukin-2 after in vivo administration. J Immunol 130:2203Google Scholar
  6. 6.
    Ettinghausen SE, Rosenberg SA (1986) Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2. Cancer Res 46:2784Google Scholar
  7. 7.
    Fidler IJ (1985) Macrophages and metastases-a biological approach to cancer therapy. Presidential address. Cancer Res 45:4714Google Scholar
  8. 8.
    Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823CrossRefPubMedGoogle Scholar
  9. 9.
    Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA (1983) Lymphokine-activated killer cell phenomenon II: Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymusderived lymphocytes and natural killer cells. J Exp Med 157:884Google Scholar
  10. 10.
    Hamuro J, Chihara G (1985) Lentinan, a T-cell oriented immunopotentiator: its experimental and clinical applications and possible mechanism of immune modulation. In: Immune modulating agents and their mechanisms. Marcel Dekker, New York, p 409Google Scholar
  11. 11.
    Hamuro J, Wagner H, Rollinghoff M (1978) β(1–3)-Glucans as a probe for T cell specific immune adjuvants. II. Enhanced in vitro generation of cytotoxic T lymphocytes. Cell Immunol 38:328Google Scholar
  12. 12.
    Hamuro J, Rollinghoff M, Wagner H (1980) Induction of cytotoxic peritoneal exudate cells by T-cell immune adjuvants of the β(1,3) glucan-type lentinan and its analogues. Immunology 39:551Google Scholar
  13. 13.
    Henney CS, Kuribayashi K, Kern DE, Gills S (1981) Interleukin-2 augments natural killer cell activity. Nature 291:335Google Scholar
  14. 14.
    Herberman RB, Nuun-Hargrove ME (1981) Augmentation of natural killer (NK) cell activity by lentinan. In: Aoki T, Urushizaki I, Tsubura E (eds) Manipulation of host defense mechanisms. Excerpta Medica, Amsterdam, p 188Google Scholar
  15. 15.
    Izawa M, Ohno K, Amikura K, Hamuro J (1983) Lentinan augments the production of interleukin 3 and colony stimulating factor(s) by T cells. In: Aoki T, Tsubura E, Urushizaki I (eds) Manipulation of host defence mechanisms. Excerpta Medica, Amsterdam, p 59Google Scholar
  16. 16.
    Kawase I, Brooks CG, Kuribayashi K, Olabuenaga S, Newman W, Gillis S, Henney CS (1983) Interleukin 2 induces γ-interferon production: participation of macrophages and NK-like cells. J Immunol 131:288Google Scholar
  17. 17.
    Lafreniere R, Rosenberg SA (1985) Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res 45:3735Google Scholar
  18. 18.
    Mule JJ, Shu S, Schwarz SL, Rosenberg SA (1984) Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225:1487Google Scholar
  19. 19.
    Mule JJ, Shu S, Rosenberg SA (1985) The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo. J Immunol 135:646Google Scholar
  20. 20.
    Ortaldo JR, Mason A, Overton R (1986) Lymphokine-activated killer cells: analysis of progenitors and effectors. J Exp Med 164:1193Google Scholar
  21. 21.
    Rose WC, Reed III FC, Siminoff P, Bradner WT (1984) Immunotherapy of Madison 109 lung carcinoma and other murine tumors using lentinan. Cancer Res 44:1368Google Scholar
  22. 22.
    Rosenberg SA, Lotze MT, Muul LM, Leitman S, Change AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485PubMedGoogle Scholar
  23. 23.
    Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL (1985) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 161:1169Google Scholar
  24. 24.
    Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889PubMedGoogle Scholar
  25. 25.
    Sone S (1986) Role of alveolar macrophages in pulmonary neoplasias. Biochim Biophys Acta 823:227Google Scholar
  26. 26.
    Sone S, Inamura N, Nii A, Ogura T (1988) Heterogeneity of human lymphokine (IL-2)-activated killer (LAK) precursors and regulation of their LAK induction by blood monocytes. Int J Cancer 42:428Google Scholar
  27. 27.
    Suga T, Shiio T, Maeda YY, Chihara G (1984) Antitumor activity of lentinan in murine syngeneic and autochthnous hosts and its suppressive effect on 3-methylcholanthrene-induced carcinogenesis. Cancer Res 44:5132Google Scholar
  28. 28.
    Takenaga K (1984) Enhanced metastatic potential of cloned low-metastatic Lewis lung carcinoma cells. Cancer Res 44:1122Google Scholar
  29. 29.
    West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK (1987) Constant-infusion of recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898PubMedGoogle Scholar
  30. 30.
    Winkelhake JL, Stampfl S, Zimmerman RJ (1987) Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models. Cancer Res 47:3948Google Scholar
  31. 31.
    Yagi M, Yamashita T, Tsubura E (1985) Effect of a thymic factor, thymostimulin, on growth and pulmonary metastases of Lewis lung carcinoma. Cancer Immunol Immunother 19:198Google Scholar
  32. 32.
    Yokota S, Shirasaka T, Nishikawa H, Hosoe S, Ikeda T, Komuta K, Kawase I, Masuno T, Ogura T, Kishimoto S (1988) Augmentative effect of Nocardia rubra cell-wall skeleton (N-CWS) on lymphokine-activated killer (LAK) cell induction. Cancer Immunol Immunother 26:11Google Scholar
  33. 33.
    Yoshimoto R, Akiyama Y, Hayami T, Iguchi Y, Izawa M, Hamuro J (1982) Augmentation of interleukin 1 production by antitumor polysaccharide, lentinan and its role in the generation of effector T cells against tumors. Int J Immunopharmacol 4:267Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • Ken-ichiro Yamasaki
    • 1
  • Saburo Sone
    • 1
  • Takashi Yamashita
    • 1
  • Takeshi Ogura
    • 1
  1. 1.3rd Department of Internal MedicineThe University of Tokushima School of MedicineTokushimaJapan

Personalised recommendations